Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Psyence BiomedicalPBM +9.64%14 EBIT per Share is $-20.64 as of Mar. 2026. GuruFocus rates PBM with a GF Score™ of 14/100. The stock has 4 warning signs investors should review. Among 1,170 Biotechnology companies, Psyence Biomedical ranks better than 96.67% on this metric.
Psyence Biomedical's EBIT per Share for the
six
months ended in Mar. 2026 was $-8.95.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-20.64.
During the past 3 years, the average EBIT per Share Growth Rate was 78.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Psyence Biomedical's EBIT per Share or its related term are showing as below:
PBM'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 42.4 Med: 60.45 Max: 78.5
Current: 78.5
During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of Psyence Biomedical was 78.50% per year. The lowest was 42.40% per year. And the median was 60.45% per year.
PBM's 3-Year EBIT Growth Rate is ranked better than 96.67% of 1170
companies
in the Biotechnology industry
Industry Median: 15.55
vs PBM: 78.50
Psyence Biomedical (NAS:PBM) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Psyence Biomedical EBIT per Share Related Terms
Psyence Biomedical EBIT per Share Historical Data
* Premium members only.
The historical data trend for Psyence Biomedical's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-20.64
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Psyence Biomedical (PBM) has a EBIT per Share of $-20.64 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Psyence Biomedical and its competitors. According to the industry distribution chart, Psyence Biomedical ranks #39 out of 1170 companies in the Biotechnology industry, placing it in the top 3.3%.
Is Psyence Biomedical's EBIT per Share too high?
Psyence Biomedical's current EBIT per Share is $-20.64. Based on the distribution chart, Psyence Biomedical ranks #39 out of 1170 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Psyence Biomedical has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Psyence Biomedical's EBIT per Share compare to NRSN and PLUR?
According to the Biotechnology industry distribution chart, Psyence Biomedical ranks #39 out of 1170 companies for EBIT per Share. This places Psyence Biomedical in the top 3% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 15.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.55, based on 1,170 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Psyence Biomedical and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Psyence Biomedical's current EBIT per Share is $-20.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Psyence Biomedical stock overvalued right now?
Psyence Biomedical (PBM) has a current EBIT per Share of $-20.64. The current EBIT per Share is $-20.64. Psyence Biomedical's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Psyence Biomedical (PBM), the current EBIT per Share is $-20.64 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
14GF Score
Get the complete analysis for PBM
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBM has been successfully added to your 
